Grifols (NASDAQ:GRFS) Sees Unusually-High Trading Volume – What’s Next?

Shares of Grifols, S.A. (NASDAQ:GRFS) saw an uptick in trading volume on Thursday . 1,622,142 shares traded hands during mid-day trading, an increase of 102% from the previous session’s volume of 804,488 shares.The stock last traded at $8.41 and had previously closed at $7.94.

Analyst Ratings Changes

Separately, Morgan Stanley started coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Price Performance

The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. The firm has a fifty day moving average price of $7.40 and a two-hundred day moving average price of $8.10. The stock has a market capitalization of $5.80 billion, a P/E ratio of 7.21 and a beta of 0.40.

Hedge Funds Weigh In On Grifols

Several institutional investors and hedge funds have recently modified their holdings of the stock. Principal Street Partners LLC purchased a new stake in shares of Grifols during the fourth quarter valued at $84,000. Vident Advisory LLC boosted its position in shares of Grifols by 55.5% during the fourth quarter. Vident Advisory LLC now owns 29,662 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 10,590 shares during the last quarter. Soleus Capital Management L.P. boosted its position in shares of Grifols by 46.1% during the fourth quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company’s stock valued at $49,144,000 after buying an additional 2,083,722 shares during the last quarter. Tidal Investments LLC boosted its position in shares of Grifols by 49.3% during the fourth quarter. Tidal Investments LLC now owns 24,638 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 8,138 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its position in shares of Grifols by 22.7% during the fourth quarter. Quantinno Capital Management LP now owns 128,303 shares of the biotechnology company’s stock valued at $955,000 after buying an additional 23,758 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.